Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Inventory

Cash effect of the change in inventory; building inventory consumes cash.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Inventory · Q1 FY2026 · quarter ended Mar 2026

Inventory growth accelerates

Q1 FY2026 inventory of $3.21M (cash outflow) rose 26.3% year over year, ahead of the -361.9% change in trailing-twelve-month inventory. Over 3 fiscal years it compounded at -65.3% a year.

Context

  • Inventory amounted to 0.9% of revenue in FY2025, down 4.5 pp from a year earlier.
  • Inventory grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +26.3% holds above the trailing-twelve-month pace of -361.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.21M-191.4% QoQ
Last fiscal yearDec 2025
-$1.42M-82.9% YoY
LTMMar 2026
-$2.09M-361.9% YoY
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.3%——
1 year-82.9%——
3-year CAGR-65.3%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the cash flow

Latest · FY2025
(1.42M) USD
Year-over-year change
+82.9%

Inventory vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's LTM Mar 2026 inventory of $2.09M is the 2nd largest of the 3 companies compared; the peer median is $4.9M.
  • Its year-over-year change of -361.9% is the lowest of 3, against a peer median of -91.7%.
  • Inventory amounts to 1.3% of revenue for PACB, versus a peer median of 32.3%.
PACB Competitors Peer median
Inventory for PACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ILMNIllumina, Inc.LTM Jun 2026$11M -54.2%-49.9%0.2%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$2.09M -361.9%-65.3%1.3%
QSIQuantum-Si incorporatedLTM Mar 2026$1.19M -129.3%—64.3%
Peer median (excluding PACB) $4.9M-91.7%-49.9%32.3%

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(181.22M)(314.25M)(306.74M)(309.85M)(546.38M)
Depreciation & Amortization11.59M17.32M32.69M53.34M386.41M
Deferred Income Tax(93.65M)0(11.42M)(205K)(546K)
Stock-Based Compensation80.73M78.61M0041.67M
Change in Working Capital21.01M(53.97M)(58.96M)(40.58M)4.44M
Accounts Receivables(7.17M)5.46M(17.83M)9.09M(7.92M)
Inventory(12.43M)(33.91M)(13.84M)(8.32M)(1.42M)
Accounts Payables6.36M1.03M206K1.41M2.48M
Other Working Capital34.24M(26.55M)(27.49M)(42.75M)11.3M
Other Non-Cash Items50.37M9.08M77.88M91.24M3.19M
Operating Cash Flow(111.18M)(263.21M)(266.55M)(206.06M)(111.21M)
Capital Expenditures(5.93M)(16.93M)(8.84M)(6.19M)(2.71M)
Acquisitions (Net)(319.79M)179K(102K)00
Purchases of Investments(988.05M)(442.79M)(756.57M)(498.64M)(216.91M)
Sales of Investments635.24M575.8M770.12M628.83M340.07M
Other Investing Activities0(179K)00(5M)
Investing Cash Flow(678.53M)116.08M4.6M124M115.45M
Debt Repayment895.18M(1.61M)(1.84M)(50.69M)0
Common Stock Issued294.85M11.23M204.52M7.7M3.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.44M)0(86.41M)00
Financing Cash Flow1.17B9.62M116.27M(42.99M)3.43M
Effect of Forex Changes00500K890K0
Net Change in Cash379.87M(137.51M)(145.18M)(124.15M)7.67M
Free Cash Flow(117.11M)(280.14M)(275.39M)(212.25M)(113.92M)

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.